Advice
following a full submission:
dexmedetomidine (Dexdor®) is accepted for use within NHS Scotland.
Indication under review: for sedation in adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale [RASS] 0 to -3).
Dexmedetomidine was as effective as propofol and midazolam in maintaining the target depth of sedation in ICU patients. The median duration of mechanical ventilation was numerically shorter with dexmedetomidine than with propofol and significantly shorter than with midazolam.
Download detailed advice167KB (PDF)
Medicine details
- Medicine name:
- dexmedetomidine hydrochloride (Dexdor)
- SMC ID:
- 784/12
- Indication:
- For sedation of adult ICU patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
- Pharmaceutical company
- Orion Pharma (UK) Ltd
- BNF chapter
- Anaesthesia
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 June 2012